Clinical Study
Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients
Table 1
Baseline characteristics of patients.
| | | Alendronate
() | Control
() | value |
| | Age (years) | 52.8 ± 12.6 | 52.9 ± 7.3 | NS | | Male (%) | 80 | 57 | NS | | Diabetes (%) | 40 | 43 | NS | | HTN (%) | 80 | 71 | NS | | Tac (%) | 80 | 86 | NS | | Steroid (mg/day) | 5 | 4.7 | NS | | HD vintage (months) | 136.8 ± 142.3 | 71.1 ± 76.6 | NS | | Transplant vintage (months) | 59.6 ± 58.5 | 45.3 ± 42.3 | NS |
|
|
HTN: hypertension; Tac: tacrolimus; NS: not significant.
|
